Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty 100 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Torrent Pharma reported strong Q3 FY26 results with consolidated revenue of ₹3,303 crores, up 18% year-on-year, driven by robust growth in India (₹1,798 cr, +14%), Brazil (₹371 cr, +27%), and the US (₹321 cr, +19%). Operating EBITDA rose 19% YoY to ₹1,088 crores with margins steady at 33%. Net profit after tax grew 26% YoY to ₹635 crores, while 9M FY26 PAT also rose 26% to ₹1,774 crores. The company declared an interim dividend of ₹29 per share (580%), payable around March 6, 2026. The board also confirmed completion of the acquisition of a controlling stake in JB Chemicals & Pharmaceuticals, with the company obtaining control effective January 21, 2026 and a proposed merger swap ratio of 51 Torrent shares for every 100 JB Pharma shares.
Strong all-round earnings with 26% PAT growth, healthy double-digit revenue expansion across major markets, and a generous interim dividend are positive for shareholders. The completed JB Pharma acquisition significantly scales up the business, making Torrent the 5th largest pharma company in India, though integration risks and pending SEBI/NCLT approvals remain to watch.